Zydus Cadilla has received approval for a critical HIV treatment and prevention generic. The Food and Drug Administration has approved Zydus Cadila’s generic of Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate tablets in a dosage strength of 200 mg/300 mg).
It is used with other HIV medications to help control HIV infection, and it also helps to decrease the amount of HIV in the body so the immune system can work better.
The FDA also has tentatively approved Zydus Cadila's generic in dosage strengths of 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg dosage.
Zydus Cadila’s product will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.